List of Fanapt drug patents
Fanapt is owned by Vanda Pharms Inc.
Fanapt contains Iloperidone.
Fanapt has a total of 9 drug patents out of which 0 drug patents have expired.
Fanapt was authorised for market use on 06 May, 2009.
Fanapt is available in tablet;oral dosage forms.
Fanapt can be used as method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine, dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone, method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6, dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone.
The generics of Fanapt are possible to be released after 28 December, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(2 years from now) | |
| US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(4 years from now) | |
| US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(7 years from now) | |
| US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(7 years from now) | |
| US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(7 years from now) | |
| US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(7 years from now) | |
| US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(7 years from now) | |
| US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(7 years from now) | |
| US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(8 years from now) | |
Drugs and Companies using ILOPERIDONE ingredient
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine; Method of treating schizophrenia by administering ilo...
Dosage: TABLET;ORAL
FANAPT family patents
51
United States
12
European Union
10
Japan
8
Canada
6
Spain
3
Slovenia
2
Hungary
2
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic